Know Labs Stock Price, News & Analysis
Company Description
Know Labs, Inc. (historically trading under the ticker KNW) is a public company that has focused on the development and application of radio frequency spectroscopy and radio frequency dielectric spectroscopy (RFDS) for medical diagnostics and other fields of use. According to multiple company disclosures, its platform technology directs electromagnetic energy through a substance or material to capture a unique molecular signature, which can then be used to identify and monitor analytes that have traditionally required invasive and/or expensive and time‑consuming lab-based tests.
The company has described itself as a pioneering leader in RFDS, with a patented and patent‑pending technology platform designed to integrate into a variety of wearable, mobile or bench‑top form factors. In its public communications, Know Labs has repeatedly highlighted that among its first expected applications of this platform is a product marketed as a non‑invasive glucose monitor. This device is designed to provide users with accessible, real‑time information on blood glucose levels and will require clearance from the U.S. Food and Drug Administration (FDA) prior to introduction to the market.
Beyond glucose monitoring, Know Labs has emphasized that its RFDS technology can be applied across multiple domains. Company materials describe the ability of its sensors to monitor analytes relevant to medical diagnostics, and they also reference potential uses in pharmaceutical manufacturing and food quality and safety. For example, research conducted in the company’s laboratory has demonstrated that its RFDS sensor can identify changes in pH levels in real time without direct contact with a liquid, detecting changes from outside a pipe using a model based on Fourier analysis. This work aligns with the company’s stated historic focus on medical diagnostics and proof‑of‑concept research in blood glucose monitoring, while also exploring broader industrial and safety applications.
To support commercialization and broader adoption of its RFDS platform, Know Labs has created a dedicated licensing division called Know Labs Technology Licensing (KTL). KTL is described as facilitating the global adoption of the company’s patented RFDS technology through a structured licensing framework. Public descriptions of KTL note that it works with corporations, universities, and research institutions, and that it leverages an extensive intellectual property portfolio and a proprietary e‑RFDS© digital watermark to help licensees protect developments from counterfeiting and unauthorized use.
Historically, Know Labs’ common shares traded on the NYSE American under the symbol KNW. In early 2025, the company reported that its stock began trading on the OTC Pink Market under the symbol KNWN following a 1‑for‑40 reverse stock split effective February 19, 2025. The company disclosed that this reverse split was undertaken in connection with efforts to regain compliance with NYSE American listing criteria after NYSE Regulation commenced delisting proceedings related to bid price requirements. During this period, Know Labs stated that it was appealing the delisting process and that its stock would be suspended from trading on NYSE American while the appeal was pending.
Subsequently, the company entered into and closed a private placement transaction with Goldeneye 1995 LLC, an affiliate of Greg Kidd. Under a Securities Purchase Agreement, the buyer contributed 1,000 Bitcoin and $15 million in cash in exchange for approximately 357.8 million shares of Know Labs common stock at a per‑share purchase price of $0.335, resulting in a change in control. An 8‑K filed on August 7, 2025 reports that, upon closing on August 6, 2025, Goldeneye 1995 LLC acquired approximately 81% of the issued and outstanding shares of the company on a fully diluted basis. The transaction also involved the conversion or redemption of various series of preferred stock and the repayment or conversion of certain debt instruments.
Following shareholder approval at a Special Meeting held on July 31, 2025, the company amended its Articles of Incorporation to increase authorized common stock from 7,500,000 to 750,000,000 shares and approved an amendment to its 2021 Equity Incentive Plan to increase the number of shares available for issuance. These corporate actions supported the issuance of shares in the private placement and the company’s revised capital structure.
In connection with the closing of the private placement and the company’s strategic transition, the board of directors approved a change in corporate name and trading symbol. An 8‑K filed on August 15, 2025 reports that the company completed the change of its name to USBC, Inc. and its trading symbol to USBC on the NYSE American, effective August 15, 2025. The filing also notes that the company changed the address of its principal executive offices to Reno, Nevada. As a result, the ticker KNW now represents the historical identity of the company prior to its rebranding as USBC, Inc. and the subsequent symbol change.
Public statements following the acquisition describe a multi‑disciplinary enterprise that combines Know Labs’ non‑invasive health monitoring research with new activities in digital assets and banking‑related technologies. Company communications state that, under new leadership, the organization is deploying a Bitcoin treasury strategy and investing in the development of the USBC token, a U.S.‑dollar denominated token operating on blockchain technology and embedded with digital identity. According to these disclosures, the token is fully redeemable and is designed to pay high‑yield rewards through a mobile application, with a focus on identity, inclusion, and risk management. At the same time, Know Labs’ founder is reported to be leading a science division that continues proprietary diagnostic research in non‑invasive medical technology.
Throughout its public filings and news releases, the company has emphasized that any non‑invasive glucose monitoring product based on its RFDS platform will require FDA clearance before market introduction, and that other products developed through its KTL program may not require such prior FDA approval. Investors reviewing the historical KNW symbol can therefore see both the legacy focus on RFDS‑based diagnostics and licensing, and the subsequent evolution toward a broader strategy that includes digital asset‑related activities under the USBC, Inc. name.
Business focus and technology
Across its disclosures, Know Labs describes its core business as centered on a platform technology that uses radio frequency spectroscopy or RFDS to capture molecular signatures. The company states that this approach can be integrated into wearable devices, mobile hardware, or bench‑top systems, and that it is intended to enable non‑invasive or less invasive measurement of analytes compared with many traditional laboratory methods. The company’s research on contactless pH measurement illustrates how RFDS can detect changes in a solution without direct sensor contact, using signal processing techniques such as inverse Fourier transforms and linear discriminant analysis.
In addition to its internal research and development, Know Labs has positioned KTL as a mechanism to extend the reach of RFDS across industries by licensing intellectual property and the e‑RFDS© digital watermark. Public descriptions highlight that this licensing model is aimed at enabling external organizations to incorporate RFDS into their own products and processes while addressing concerns about counterfeiting and unauthorized use.
Corporate evolution and capital structure
The company’s recent history includes several notable corporate events documented in SEC filings and press releases. These include a reverse stock split (1‑for‑40) effective February 19, 2025, a temporary move to trading on the OTC Pink Market under the symbol KNWN, and an appeal of NYSE American delisting proceedings related to bid price requirements. The reverse split applied to both issued and outstanding and authorized shares and was described by the company as one component of efforts to maintain a listing on NYSE American.
Subsequent steps included the bridge financing arrangement with Goldeneye 1995 LLC, the shareholder approvals at the July 31, 2025 Special Meeting, and the August 6, 2025 closing of the private placement that resulted in a change in control. After these events, the company implemented the name and ticker change to USBC, Inc. (USBC) and reported the adoption of indemnification agreements for directors and officers, as well as the maintenance of directors’ and officers’ liability insurance.
Status of the KNW ticker
For users researching the historical KNW symbol, it is important to note that official filings confirm that the company has changed its corporate name to USBC, Inc. and its trading symbol to USBC on the NYSE American, effective August 15, 2025. Earlier in 2025, the company also reported that its shares traded on the OTC Pink Market under the symbol KNWN during a period when it was addressing NYSE American listing criteria. The KNW symbol therefore primarily reflects the company’s identity and activities prior to the completion of these corporate changes and the adoption of the USBC symbol.